4-methyl-2',4'-dimethoxybiphenyl | 58005-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-2',4'-dimethoxybiphenyl
• 英文别名: 2,4-dimethoxy-4′-methyl-1,1′-biphenyl；2,4-Dimethoxy-1-(4-methylphenyl)benzene
• CAS: 58005-47-3
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: QYZQYRZOOMNZFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-碘甲苯 、 2,4-二甲氧基苯硼酸 在 potassium phosphate 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以50%的产率得到4-methyl-2',4'-dimethoxybiphenyl
  参考文献：
  名称：

  铃木-Miyaura偶联的分子/多相镍催化剂

  摘要：

  设计并合成了一种基于富含稀土的镍催化剂和SiO 2载体的分子/非均相催化剂基序。表征和催化测试表明，附着在高表面积SiO 2载体上的分子镍催化剂[（2,2'：6'，2'-叔吡啶-4'-苯甲酸）Ni（II）] Cl 2是活性交叉偶联催化剂和提高的产品收率是由于催化剂附着在SiO 2上时分子稳定性提高的结果支持。这种分子/异质基序很容易从反应混合物中分离出来，并可循环用于多种催化反应。该催化剂在低至0.1 mol％的催化剂负载量下对Suzuki-Miyaura催化具有活性，并且已经实现了接近2000的周转率。

  DOI：

  10.1021/acs.organomet.9b00082

文献信息

• RHO-KINASE INHIBITORS
  申请人：Nagarathnam Dhanapalan

  公开号：US20070238741A1

  公开（公告）日：2007-10-11

  Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

  本发明涉及化合物及其衍生物、合成方法以及它们作为Rho-激酶抑制剂的用途。本发明的这些化合物可用于抑制肿瘤生长、治疗勃起功能障碍以及治疗其他由Rho-激酶介导的适应症，例如冠心病。
• Antituberculous composition comprising oxazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP2269694A2

  公开（公告）日：2011-01-05

  The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as secondary antituberculous drugs.

  本发明提供了效力更高的抗结核治疗药物。本发明还提供了含有由(I)通式(1)代表的噁唑化合物的抗结核治疗药物：[其中R1代表氢原子或C1-6烷基，n代表0-6的整数，R2代表通式(A)或类似物，其中R代表苯氧基（至少一个选自卤素原子、任选卤素取代的C1-6烷基和任选卤素取代的C1-6烷氧基组成的组中的基团可在苯基环上被取代）或类似物]，其光学活性形式或其盐，以及药物(II)如二级抗结核药物。
• An Active, General, and Long-Lived Palladium Catalyst for Cross-Couplings of Deactivated (Hetero)aryl Chlorides and Bromides with Arylboronic Acids
  作者：Takashi Hoshi、Tomonobu Honma、Ayako Mori、Maki Konishi、Tsutomu Sato、Hisahiro Hagiwara、Toshio Suzuki

  DOI：10.1021/jo402089r

  日期：2013.11.15

  An active, general, and long-lived palladium catalyst for Suzuki-Miyaura reactions of aryl and heteroaryl chlorides deactivated by steric hindrance, electron richness, and coordinating functional groups is reported. In reactions of arylbromide bearing two o-tert-butyl substituents, C(sp(3))-H arylation of the tert-butyl group, rather than the Suzuki-Miyaura reaction, proceeded in excellent yield. The key to the success of the reactions was the development of biphenylene-substituted dicyclohexylruthenocenylphosphine (CyR-Phos) as a supporting ligand.
• Kang, Suk-Ku; Ryu, Hyung-Chul; Son, Hoe-Joo, Synlett, 1998, # 7, p. 771 - 773
  作者：Kang, Suk-Ku、Ryu, Hyung-Chul、Son, Hoe-Joo

  DOI：——

  日期：——
• ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS
  申请人：Matsumoto Makoto

  公开号：US20090275528A1

  公开（公告）日：2009-11-05

  The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R 1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R 2 represents general formula (A) or the like, wherein R 3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.